InMode Ltd.

InMode Ltd. (INMD) is currently trading at $13.54, with a 52-week range of $12.72 to $16.74. Reaching the $16 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.

Wall Street analysts currently have a consensus price target of $17.0 for InMode Ltd., with a None rating, and the most bullish analysts see the stock reaching as high as $21.0. Whether InMode Ltd. can reach $16 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.

Historically, INMD has delivered a -20.2% CAGR over the past 5 years, which suggests the stock has demonstrated meaningful long-term growth momentum. However, past performance does not guarantee future results, and short-term price movements can be influenced by macroeconomic shifts, interest rate changes, and investor sentiment. Use the INMD Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.

Whether InMode Ltd. (INMD) is worth buying at $13.54 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:

Valuation: InMode Ltd. trades at a Price-to-Earnings (P/E) ratio of 9.8x, which can be compared against other Healthcare companies to assess whether the stock is expensive or attractively priced relative to its peers.

Profitability & efficiency: InMode Ltd. has a Return on Capital Employed (ROCE) of 12.3%, which reflects modest capital efficiency. Its Return on Equity (ROE) stands at 13.3%.

Financial health: The Debt-to-Equity ratio of 1.2 indicates a moderate level of leverage, which is common in capital-intensive industries.

Analyst view: The Wall Street consensus recommendation for INMD is currently None, with a mean price target of $17.0 based on 4 analyst ratings. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.

As of 2026, Wall Street analysts have set a consensus (mean) price target of $17.0 for InMode Ltd. (INMD), aggregated from 4 analyst ratings. The overall analyst recommendation is None.

The price target range spans from $15.0 on the bearish end to $21.0 on the most optimistic projection, with a median target of $16.0. This wide range reflects differing views on InMode Ltd.'s growth prospects, competitive positioning, and macroeconomic sensitivity.

It is important to note that analyst price targets are forward-looking estimates based on financial models, earnings projections, and sector assumptions — they are not guarantees. Targets are regularly revised following quarterly earnings results, management guidance updates, or shifts in the broader economic outlook. Stocks can trade significantly above or below analyst targets depending on market conditions. View the full analyst breakdown and track target revisions on the INMD analysis page on StockSifting.

InMode Ltd. (INMD) currently has a Price-to-Earnings (P/E) ratio of 9.8x, meaning investors are paying $9.8 for every $1 of the company's trailing twelve-month earnings. Whether this makes the stock overvalued depends on several contextual factors:

Sector context: The Healthcare sector tends to command higher valuation multiples when growth expectations are elevated. A 9.8x P/E is relatively low, which could indicate an undervalued opportunity — or it may reflect lower expected growth or higher perceived risk.

Growth-adjusted valuation: A P/E ratio in isolation can be misleading. Fast-growing companies often deserve higher P/E multiples because their future earnings are expected to rise significantly. A more complete picture comes from looking at the PEG ratio (P/E divided by earnings growth rate) — a PEG below 1 is often considered undervalued, while above 2 may signal overvaluation. InMode Ltd.'s ROCE of 12.3% suggests it has moderate capital returns.

Additional metrics to review: P/E is just one lens. Compare it alongside the Price-to-Book (P/B) ratio, EV/EBITDA, Price-to-Sales, and free cash flow yield for a more complete valuation picture. View all of INMD's valuation ratios on StockSifting's ratios section. Valuation is subjective and context-dependent — this is not investment advice.

Projecting InMode Ltd. (INMD)'s stock price 3 years into the future — to 2029 — requires making assumptions about the company's earnings growth, valuation multiple, and broader market conditions. No projection is guaranteed, but historical growth rates offer a reasonable starting point.

Based on INMD's historical 5-year Compound Annual Growth Rate (CAGR) of -20.2%, if that rate of growth were to continue, the stock could reach approximately $7 by 2029 — up from its current price of $13.54. This projection assumes the historical CAGR holds, which depends on InMode Ltd. sustaining its revenue growth, maintaining profit margins, and the market continuing to reward it at a similar valuation multiple.

In reality, stock prices rarely follow a straight-line trajectory. Short-term volatility, earnings misses, sector rotations, interest rate changes, and macroeconomic events can all cause significant deviations from any modeled path. Investors with a 3-year horizon should focus on the fundamental business trajectory — revenue growth, expanding margins, and free cash flow generation — rather than short-term price fluctuations.

You can model different scenarios — conservative, base, and bull case — using the INMD Return Calculator on StockSifting. Enter any investment amount and CAGR assumption to see projected outcomes over your chosen time horizon. All projections are mathematical estimates only and do not constitute financial advice.